Vertex Pharmaceuticals News Releases https://investors.vrtx.com/ Vertex Pharmaceuticals News Releases en Vertex Expands into New Disease Areas and Enhances Gene Editing Capabilities Through Expanded Collaboration with CRISPR Therapeutics and Acquisition of Exonics Therapeutics https://investors.vrtx.com/news-releases/news-release-details/vertex-expands-new-disease-areas-and-enhances-gene-editing -Provides Vertex with leading gene editing capabilities to develop novel therapies for Duchenne Muscular Dystrophy and Myotonic Dystrophy Type 1- -CRISPR to receive an upfront payment of $175 million , with potential for additional milestone and royalty payments- -Exonics to be acquired for an Thu, 06 Jun 2019 17:12:00 -0400 Vertex Pharmaceuticals News Releases 26231 Vertex to Present Data at ECFS Conference on Potential Impact of Early Treatment and Long-Term Treatment with CFTR Modulators on the Underlying Cause of CF https://investors.vrtx.com/news-releases/news-release-details/vertex-present-data-ecfs-conference-potential-impact-early BOSTON --(BUSINESS WIRE)--Jun. 4, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data from six scientific abstracts from the company’s portfolio of cystic fibrosis (CF) medicines will be presented at the 42 nd European Cystic Fibrosis Conference , taking place June Tue, 04 Jun 2019 08:00:00 -0400 Vertex Pharmaceuticals News Releases 26181 Vertex Selects Triple Combination Regimen of VX-445, Tezacaftor and Ivacaftor to Submit for Global Regulatory Approvals in Cystic Fibrosis https://investors.vrtx.com/news-releases/news-release-details/vertex-selects-triple-combination-regimen-vx-445-tezacaftor-and -Mean absolute improvement in ppFEV 1 of 14.3 percentage points from baseline through week 24 of treatment compared to placebo (p Thu, 30 May 2019 08:00:00 -0400 Vertex Pharmaceuticals News Releases 26176 Vertex and Kymera Therapeutics Establish Strategic Collaboration to Discover and Develop Targeted Protein Degradation Medicines for Serious Diseases https://investors.vrtx.com/news-releases/news-release-details/vertex-and-kymera-therapeutics-establish-strategic-collaboration -Multi-year collaboration leveraging Kymera’s proprietary targeted protein degradation platform to develop novel medicines- -Kymera to receive $70 million upfront, including equity investment, and potential additional milestone and royalty payments for up to six programs in the collaboration- Wed, 15 May 2019 08:30:00 -0400 Vertex Pharmaceuticals News Releases 26126 Vertex Reports First-Quarter 2019 Financial Results https://investors.vrtx.com/news-releases/news-release-details/vertex-reports-first-quarter-2019-financial-results - First-quarter 2019 product revenues of $857 million , a 34% increase compared to $638 million in 2018- - First-quarter 2019 GAAP operating income increased 115% to $277 million ; non-GAAP operating income increased 81% to $377 million - - On track to choose best triple combination regimen in Q2 Tue, 30 Apr 2019 16:01:00 -0400 Vertex Pharmaceuticals News Releases 26081 FDA Approves KALYDECO® (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants with CF as Early as Six Months of Age https://investors.vrtx.com/news-releases/news-release-details/fda-approves-kalydecor-ivacaftor-first-and-only-cftr-modulator -Opportunity to treat the underlying cause of CF earlier than ever before- -Safety data from Phase 3 ARRIVAL study support treatment with KALYDECO in children ages six to Tue, 30 Apr 2019 08:30:00 -0400 Vertex Pharmaceuticals News Releases 26071 CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Beta Thalassemia https://investors.vrtx.com/news-releases/news-release-details/crispr-therapeutics-and-vertex-announce-fda-fast-track-0 ZUG, Switzerland and CAMBRIDGE and BOSTON, Mass. – April 16, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for CTX001 for the Tue, 16 Apr 2019 07:00:00 -0400 Vertex Pharmaceuticals News Releases 26041 Vertex to Announce First-Quarter 2019 Financial Results on April 30 https://investors.vrtx.com/news-releases/news-release-details/vertex-announce-first-quarter-2019-financial-results-april-30 BOSTON --(BUSINESS WIRE)--Apr. 12, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2019 financial results on Tuesday, April 30, 2019 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET . Fri, 12 Apr 2019 08:00:00 -0400 Vertex Pharmaceuticals News Releases 26026 Vertex Appoints Charles Wagner as Chief Financial Officer https://investors.vrtx.com/news-releases/news-release-details/vertex-appoints-charles-wagner-chief-financial-officer BOSTON --(BUSINESS WIRE)--Apr. 2, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the appointment of Charles (Charlie) Wagner as Executive Vice President and Chief Financial Officer (CFO), effective April 10, 2019 . Mr. Wagner will report directly to Vertex Chairman, Tue, 02 Apr 2019 08:00:00 -0400 Vertex Pharmaceuticals News Releases 26011 Vertex Receives Approval for SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) in Australia, to Treat the Underlying Cause of Cystic Fibrosis in People aged 12 and Older with Certain CFTR Gene Mutations https://investors.vrtx.com/news-releases/news-release-details/vertex-receives-approval-symdekor-tezacaftorivacaftor-and -A new treatment option for patients with two copies of the F508del mutation, the most common mutation in cystic fibrosis- -First medicine in Australia to treat the underlying cause of cystic fibrosis in patients who have certain mutations that result in residual CFTR function- BOSTON --(BUSINESS Tue, 12 Mar 2019 05:07:00 -0400 Vertex Pharmaceuticals News Releases 26001